CDC awards $15.88 million to Wayne State University to study viral infection surveillance

The U.S. Centers for Disease Control and Prevention has awarded $15.88 million to the Wayne State University School of Medicine's Department of Emergency Medicine to be the epicenter of a national study on viral infections that present in emergency departments across the county.

The project, "Enhancing U.S. Surveillance of Laboratory Confirmed SARS-CoV-2, Influenza, and Other Respiratory Viruses through a Network of Emergency Departments," will continue for three years.

Jeffrey Kline, M.D., professor and associate chair of Research for the Department of Emergency Medicine, is the overall principal investigator on the project, which will spread to emergency departments in 21 states and the District of Columbia, and 100 hospitals for surveillance of viral infections. Data will be obtained from the electronic medical records at the participating hospital systems. Each participating system will receive a portion of the $15.88 million and will have an on-site principal investigator.

The project will run now through August 2024. "If we are successful at the end of year three, we hope for this to be renewed for years to come," Dr. Kline said.

The study is based on the Registry of suspected COVID-19 in Emergency Care, or RECOVER, a large clinical registry of patients from 155 emergency departments in 27 states tested for SARS-CoV-2 from March to September 2020, which Dr. Kline founded.

This study network will be known as RECOVER-CDC.

Patients will be identified based upon their reason, or chief complaint, for visiting the emergency department.

We will report data on patients who have chief complaints suggestive of viral syndromes, including but not limited to cough, fever, muscle aches, sore throat, nasal congestion and respiratory distress. We will then determine how many are being tested for SARS-CoV-2, influenza, respiratory syncytial virus and other viruses as part of usual care and, importantly, their vaccination status. We will then follow the patients to determine if they are admitted to the hospital or not, and their outcomes and diagnoses within 30 days."

Dr. Jeffrey Kline, M.D., professor and associate chair of research, Department of Emergency Medicine

The researchers aim to determine the frequency of testing symptomatic patients for viral infections, the results of those tests, the outcomes and diagnoses of patients with known or suspected viral infections, and the associations of outcomes with vaccine status.

"We will have many other questions. For example, of key interest for my own research is the association of viral infections with the diagnosis of blood clots," Dr. Kline said.

The study team includes Assistant Vice President of Research and Professor of Emergency Medicine Phillip Levy, M.D., as co-investigator; Professor of Emergency Medicine and Director of Biostatistics, Epidemiology and Research Design Core Robert Welch, M.D., for analytics oversight; and BERD Core statistician Liying Zhang, Ph.D., with initial support from the Department of Emergency Medicine's Director of Grants Management LynnMarie Mango, M.P.H.

The award number for this Centers for Disease Control and Prevention contract is 75D30121C11813.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Futuristic AI-powered virtual lab designs potent SARS-CoV-2 nanobodies